Lantheus Holdings, Inc. (LNTH) Insider Trading

Last 12 months

No open-market buying or selling by insiders.

The last open-market buy by an executive or director was in Mar 2021.

Net open-market

0 buys · 0 sales

Under a 10b5-1 plan

—

no sales

Insiders who bought / sold

0 / 0

executives and directors

Last open-market buy

Mar 2021

Mar 5, 2021

Get an email when LNTH's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Aug 19, 2025 – Aug 20, 2025	Mark C Wehrly Other	SoldNo plan 2 parts	3,406,000	$56.14 average	$191M	49%	Form 4
Aug 19, 2025 – Aug 20, 2025	Joshua J. Dapice Other	SoldNo plan 2 parts	3,406,000	$56.14 average	$191M	49%	Form 4
Aug 13, 2025	Paul Blanchfield President	Sold10b5-1 plan	3,060	$53.57	$164k	2.7%	Form 4
Jun 13, 2025	Daniel Niedzwiecki See Remarks	Sold10b5-1 plan	6,000	$78.74	$472k	6.4%	Form 4
Jun 9, 2025	Julie McHugh Director	Sold10b5-1 plan	5,192	$81.62	$424k	17%	Form 4
Jun 9, 2025	Robert J. Marshall Jr. CFO and Treasurer	Sold10b5-1 plan 3 parts	39,773	$83.00 average	$3.3M	31%	Form 4
Jun 5, 2025	Paul Blanchfield President	Sold10b5-1 plan	6,599	$79.65	$526k	5.6%	Form 4
Jun 5, 2025	Daniel Niedzwiecki See Remarks	Sold10b5-1 plan	6,000	$79.65	$478k	6.1%	Form 4
Jun 2, 2025	Mary Anne Heino Director	Sold10b5-1 plan 2 parts	26,066	$76.83 average	$2M	4.3%	Form 4
Mar 17, 2025	Robert J. Marshall Jr. CFO and Treasurer	Sold10b5-1 plan	10,000	$100.52	$1.01M	8.1%	Form 4
Mar 13, 2025	Mary Anne Heino Director	SoldNo plan	2	$100.13	$200	<0.1%	Form 4
Mar 5, 2025	Paul Blanchfield President	Sold10b5-1 plan	2,084	$98.00	$204k	1.7%	Form 4
Mar 3, 2025	Mary Anne Heino Director	Sold10b5-1 plan 5 parts	53,107	$94.35 average	$5.01M	8.5%	Form 4
Jan 15, 2025	James H Thrall Director	Sold10b5-1 plan	1,000	$94.76	$95k	2.9%	Form 4
Nov 15, 2024	Robert J. Marshall Jr. CFO and Treasurer	Sold10b5-1 plan	10,000	$81.20	$812k	8.9%	Form 4
Nov 14, 2024	Paul Blanchfield President	Sold10b5-1 plan	2,000	$79.65	$159k	2.0%	Form 4
Nov 8, 2024	Mary Anne Heino Director	Sold10b5-1 plan 4 parts	11,487	$87.16 average	$1M	2.3%	Form 4

Aug 19, 2025 – Aug 20, 2025No plan
Mark C Wehrly
Other · sold 3,406,000 at avg $56.14
$191M
49% of stake
Aug 19, 2025 – Aug 20, 2025No plan
Joshua J. Dapice
Other · sold 3,406,000 at avg $56.14
$191M
49% of stake
Aug 13, 202510b5-1 plan
Paul Blanchfield
President · sold 3,060 at $53.57
$164k
2.7% of stake
Jun 13, 202510b5-1 plan
Daniel Niedzwiecki
See Remarks · sold 6,000 at $78.74
$472k
6.4% of stake
Jun 9, 202510b5-1 plan
Julie McHugh
Director · sold 5,192 at $81.62
$424k
17% of stake
Jun 9, 202510b5-1 plan
Robert J. Marshall Jr.
CFO and Treasurer · sold 39,773 at avg $83.00
$3.3M
31% of stake
Jun 5, 202510b5-1 plan
Paul Blanchfield
President · sold 6,599 at $79.65
$526k
5.6% of stake
Jun 5, 202510b5-1 plan
Daniel Niedzwiecki
See Remarks · sold 6,000 at $79.65
$478k
6.1% of stake
Jun 2, 202510b5-1 plan
Mary Anne Heino
Director · sold 26,066 at avg $76.83
$2M
4.3% of stake
Mar 17, 202510b5-1 plan
Robert J. Marshall Jr.
CFO and Treasurer · sold 10,000 at $100.52
$1.01M
8.1% of stake
Mar 13, 2025No plan
Mary Anne Heino
Director · sold 2 at $100.13
$200
<0.1% of stake
Mar 5, 202510b5-1 plan
Paul Blanchfield
President · sold 2,084 at $98.00
$204k
1.7% of stake
Mar 3, 202510b5-1 plan
Mary Anne Heino
Director · sold 53,107 at avg $94.35
$5.01M
8.5% of stake
Jan 15, 202510b5-1 plan
James H Thrall
Director · sold 1,000 at $94.76
$95k
2.9% of stake
Nov 15, 202410b5-1 plan
Robert J. Marshall Jr.
CFO and Treasurer · sold 10,000 at $81.20
$812k
8.9% of stake
Nov 14, 202410b5-1 plan
Paul Blanchfield
President · sold 2,000 at $79.65
$159k
2.0% of stake
Nov 8, 202410b5-1 plan
Mary Anne Heino
Director · sold 11,487 at avg $87.16
$1M
2.3% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch LNTH, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Related stocks: In Vitro & In Vivo Diagnostic Substances

NEOGNeogen Corporation

MYGNMyriad Genetics Inc.

QDELQuidelOrtho Corporation

IDXXIDEXX Laboratories, Inc.

HALOHalozyme Therapeutics Inc.

PAHCPhibro Animal Health Corporation

ALKSAlkermes plc

INDVIndivior Pharmaceuticals, Inc.

Spot a number that looks wrong? Check it in LNTH's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing LNTH

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.